Company newsMRK
Explain this story: H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation
H.C. Wainwright increased its price target for Surrozen Inc. (NASDAQ:SRZN) to $54 from $44, maintaining a Buy rating, after Merck's positive trial results validated the Wnt pathway. This validation is seen as beneficial for Surrozen's SZN-8141, which is slated to enter clinical trials for diabetic macular edema by year-end 2026. Despite a recent surge in stock price, InvestingPro analysis suggests the stock might be overvalued.
OtherInvesting.com CanadaSector and industry: HealthcareDrug ManufacturersTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
H.C. Wainwright increased its price target for Surrozen Inc. (NASDAQ:SRZN) to $54 from $44, maintaining a Buy rating, after Merck's positive trial results validated the Wnt pathway. This validation is seen as beneficial for Surrozen's SZN-8141, which is slated to enter clinical trials for diabetic macular edema by year-end 2026. Despite a recent surge in stock price, InvestingPro analysis suggests the stock might be overvalued.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.